Amgen Inc (AMGN)
- Sector
- Health Care
- Industry
- Biotechnology
- Last price
- $426.11
- As of
Kresmion compiles this page from AMGN's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
AMGEN INC (AMGN): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-05.
See the full AMGN dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for AMGN on one page. Preview it with sample data, then open it live with a free account.
Preview the AMGN dossierActive signals for AMGN
- highCONSENSUS_SELL
5 tracked funds reduced AMGN this 2026Q2, institutional consensus
- highCONSENSUS_BUY
3 tracked funds increased AMGN this 2026Q2, institutional consensus
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 9.8%, EPS $6.29 vs $5.7281 estimate
- highINSTITUTIONAL_EXIT
Point72 Asset Management, L.P. cut 64% of AMGN (2026Q2)
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 71% of AMGN (2026Q2)
FREE, NO ACCOUNT
Every signal on AMGN, as it fires
You are seeing 5 of 90 signals recorded on AMGN since 2026-05-02.
The five above landed across 3 days. The other 85 were recorded on 29 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in AMGN (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| D. E. Shaw & Co., Inc.CUSIP 031162100 · 2026Q2 | $467.2M | 0.22% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 031162100 · 2026Q2 | $408.7M | 0.30% | , |
| CITADEL ADVISORS LLCCUSIP 031162100 · 2026Q2 | $254.9M | 0.03% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 031162100 · 2026Q2 | $28.7M | 0.01% | , |
| Bridgewater Associates, LPCUSIP 031162100 · 2026Q2 | $7.9M | 0.03% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, AMGN
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
AMGN against its peers
AMGN's operating margin of 24.7% ranks in the 55th percentile of 20 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-03-31.
| Metric | AMGN | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 36.8B USD | 3.0B USD | 93 | 20 |
| Operating margin | 24.7% | 23.1% | 55 | 20 |
| Net margin | 21.0% | 13.1% | 57 | 21 |
| Return on equity | 89.1% | 11.2% | 98 | 20 |
| P / E | 29.9x | 26.5x | 63 | 11 |
| 1 year | 45.0% | 29.6% | 63 | 19 |
Peers (23): GILD, VRTX, ABBV, MRNA, REGN, NTRA, ARGX, RVMD, ONC, BIIB, ALNY, ROIV, RPRX, BNTX, UTHR, INCY, GMAB, INSM, ASND, EXEL, NBIX, SMMT, BBIO. Left out: CSLLY (no annual filing), IVBXF (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (AMGN: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow AMGN on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to AMGN for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.